Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Daiichi Sankyo (4568 JP): Enhertu Drives 9MFY26 Result; FY Guidance Reiterated

Daiichi Sankyo (4568 JP): Better-Than-Expected Q1FY26 Result; FY Guidance Reiterated

Daiichi Sankyo (4568 JP): FDA Goes Datroway, Daiichi in Contention for the Next “Enhertu” Moment

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/daiichi-sankyo-co-ltd" target="_blank" data-smartkarma-citation="entities:3014:1" rel="noopener">Daiichi Sankyo (4568 JP)</a> revealed Five-Year Business Plan (FY27–31), with an aim to emerge as a global top five oncology company as measured by ¥2.3T+ oncology revenue by 2030.</li>
<li>The company aims to deliver more than ¥3T in FY31 revenue. Operating profit of more than ¥600B is expected to be achieved by end of FY31.</li>
<li>Daiichi Sankyo will maximize the value of its DXd ADC portfolio and additional oncology pipeline through rapid market penetration of more than 20 new indications across five medicines by 2030.</li>
</ul>



Daiichi Sankyo (4568 JP) revealed Five-Year Business Plan (FY27–31), with an aim to emerge as a global top five oncology company as measured by ¥2.3T+ oncology revenue by 2030.
The company aims to deliver more than ¥3T in FY31 revenue. Operating profit of more than ¥600B is expected to be achieved by end of FY31.
Daiichi Sankyo will maximize the value of its DXd ADC portfolio and additional oncology pipeline through rapid market penetration of more than 20 new indications across five medicines by 2030.


Daiichi Sankyo (4568 JP): Ends FY26 on Mixed Note; It’s Time to Focus on Innovation Prowess